Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial
- 22 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 62 (8), 1877-1883
- https://doi.org/10.1080/10428194.2021.1888376
Abstract
Treatment-specific responses and comprehensive disease characteristics are limited in black patients with cutaneous T-cell lymphoma (CTCL). These shortcomings prompted us to perform a subgroup analysis of black patients enrolled in the MAVORIC trial – an international, randomized, phase 3 trial comparing mogamulizumab vs. vorinostat in relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS). Ten percent (N = 37) of the entire MAVORIC population (N = 372) identified as black. Significant clinical differences in black patients when compared to non-black patients included a younger median age at enrollment (53 vs. 66 years; p < 0.001), an increased frequency of MF as opposed to SS (73% vs. 52.8%; p < 0.001), and higher rates of earlier-stage disease (IB-IIA) at enrollment (37.8% vs. 21.2%; p = 0.022). Mogamulizumab offered similar response rates and progression-free survival in black patients (7.57 months) compared to the entire MAVORIC population (7.7 months) and was associated with a similar safety profile.This publication has 22 references indexed in Scilit:
- Treatment of Mycosis Fungoides With Total Skin Electron BeamAmerican Journal of Clinical Oncology, 2013
- Racial differences in mycosis fungoides: A retrospective study with a focus on eosinophiliaJournal of the American Academy of Dermatology, 2013
- Sézary syndrome: A study of 176 patients at Mayo ClinicJournal of the American Academy of Dermatology, 2012
- Age, Race, Sex, Stage, and Incidence of Cutaneous LymphomaClinical Lymphoma Myeloma and Leukemia, 2012
- Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerJournal of Clinical Oncology, 2011
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood, 2011
- Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 casesBlood, 2009
- Poor prognosis in non-Caucasian patients with early-onset mycosis fungoidesJournal of the American Academy of Dermatology, 2009
- Incidence of Cutaneous T-Cell Lymphoma in the United States, 1973-2002Archives of Dermatology, 2007
- Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary SyndromeArchives of Dermatology, 2003